| pubmed-article:16222153 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16222153 | lifeskim:mentions | umls-concept:C1704689 | lld:lifeskim |
| pubmed-article:16222153 | lifeskim:mentions | umls-concept:C0026809 | lld:lifeskim |
| pubmed-article:16222153 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
| pubmed-article:16222153 | lifeskim:mentions | umls-concept:C0008838 | lld:lifeskim |
| pubmed-article:16222153 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:16222153 | lifeskim:mentions | umls-concept:C0879262 | lld:lifeskim |
| pubmed-article:16222153 | lifeskim:mentions | umls-concept:C2349975 | lld:lifeskim |
| pubmed-article:16222153 | lifeskim:mentions | umls-concept:C1627358 | lld:lifeskim |
| pubmed-article:16222153 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:16222153 | pubmed:dateCreated | 2005-10-13 | lld:pubmed |
| pubmed-article:16222153 | pubmed:abstractText | The combination of S-1, consisting of 1 mol/l tegafur, 0.4 mol/l 5-chloro-2,4-dihydroxypyridine and 1 mol/l potassium oxonate, plus low-dose cisplatin has showed promising anti-tumor activities in experimental and clinical studies. The aim of this study was to investigate the mechanism of this combination chemotherapy. Mice bearing sarcoma-180 cells were divided into groups of seven animals each - Group A: no treatment; Group B: 5-fluorouracil (5-FU) 10 mg/kg continuous i.p. infusion; Group C: S-1 10 mg/kg p.o.; Group D: cisplatin 0.2 mg/kg i.p.; Group E: B+D; Group F: C+D. Treatments were given for 5 consecutive days, and then anti-tumor activity, the concentration of 5-FU, the thymidylate synthase inhibition rate (TSIR) and the level of 5-FU incorporated into RNA (F-RNA) in tumor tissue were evaluated. Anti-tumor activity in Group F was higher than in any other group. A significantly higher concentration of 5-FU in tumor was detected in the S-1-treated groups (C and F) than in the 5-FU-treated groups (B and E). No differences in TSIR were observed between the groups treated with 5-FU or S-1 with or without cisplatin; however, the F-RNA level in Group F was about 1.24 times significantly higher than that in Group C. Group F showed the highest anti-tumor activity, with increasing intratumoral levels of 5-FU and F-RNA, but not that of TSIR. These results suggested that the superior anti-tumor activity obtained by S-1+cisplatin might be associated with an incorporation of 5-FU into RNA. | lld:pubmed |
| pubmed-article:16222153 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16222153 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16222153 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16222153 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16222153 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16222153 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16222153 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16222153 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16222153 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16222153 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16222153 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16222153 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16222153 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16222153 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16222153 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16222153 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:16222153 | pubmed:issn | 0959-4973 | lld:pubmed |
| pubmed-article:16222153 | pubmed:author | pubmed-author:SakamotoKazuh... | lld:pubmed |
| pubmed-article:16222153 | pubmed:author | pubmed-author:SakamotoShuic... | lld:pubmed |
| pubmed-article:16222153 | pubmed:author | pubmed-author:KamanoToshiki... | lld:pubmed |
| pubmed-article:16222153 | pubmed:author | pubmed-author:YurimotoSatos... | lld:pubmed |
| pubmed-article:16222153 | pubmed:author | pubmed-author:MiyakawaAkira... | lld:pubmed |
| pubmed-article:16222153 | pubmed:author | pubmed-author:OkuzawaAtsush... | lld:pubmed |
| pubmed-article:16222153 | pubmed:author | pubmed-author:HosodaSeiyaS | lld:pubmed |
| pubmed-article:16222153 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16222153 | pubmed:volume | 16 | lld:pubmed |
| pubmed-article:16222153 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16222153 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16222153 | pubmed:pagination | 1109-14 | lld:pubmed |
| pubmed-article:16222153 | pubmed:dateRevised | 2006-4-24 | lld:pubmed |
| pubmed-article:16222153 | pubmed:meshHeading | pubmed-meshheading:16222153... | lld:pubmed |
| pubmed-article:16222153 | pubmed:meshHeading | pubmed-meshheading:16222153... | lld:pubmed |
| pubmed-article:16222153 | pubmed:meshHeading | pubmed-meshheading:16222153... | lld:pubmed |
| pubmed-article:16222153 | pubmed:meshHeading | pubmed-meshheading:16222153... | lld:pubmed |
| pubmed-article:16222153 | pubmed:meshHeading | pubmed-meshheading:16222153... | lld:pubmed |
| pubmed-article:16222153 | pubmed:meshHeading | pubmed-meshheading:16222153... | lld:pubmed |
| pubmed-article:16222153 | pubmed:meshHeading | pubmed-meshheading:16222153... | lld:pubmed |
| pubmed-article:16222153 | pubmed:meshHeading | pubmed-meshheading:16222153... | lld:pubmed |
| pubmed-article:16222153 | pubmed:meshHeading | pubmed-meshheading:16222153... | lld:pubmed |
| pubmed-article:16222153 | pubmed:meshHeading | pubmed-meshheading:16222153... | lld:pubmed |
| pubmed-article:16222153 | pubmed:meshHeading | pubmed-meshheading:16222153... | lld:pubmed |
| pubmed-article:16222153 | pubmed:meshHeading | pubmed-meshheading:16222153... | lld:pubmed |
| pubmed-article:16222153 | pubmed:meshHeading | pubmed-meshheading:16222153... | lld:pubmed |
| pubmed-article:16222153 | pubmed:meshHeading | pubmed-meshheading:16222153... | lld:pubmed |
| pubmed-article:16222153 | pubmed:meshHeading | pubmed-meshheading:16222153... | lld:pubmed |
| pubmed-article:16222153 | pubmed:meshHeading | pubmed-meshheading:16222153... | lld:pubmed |
| pubmed-article:16222153 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:16222153 | pubmed:articleTitle | Enhancement of the anti-tumor activity of S-1 by low-dose cisplatin in mice bearing the sarcoma-180 model. | lld:pubmed |
| pubmed-article:16222153 | pubmed:affiliation | Department of Coloproctological Surgery, Juntendo University School of Medicine, Tokyo, Japan, Ibaraki, Japan. | lld:pubmed |
| pubmed-article:16222153 | pubmed:publicationType | Journal Article | lld:pubmed |
